Importer of Controlled Substances; Notice of Application, 30968-30969 [2011-13207]
Download as PDF
<![CDATA[
30968
Federal Register / Vol. 76, No. 103 / Friday, May 27, 2011 / Notices
order could impact United States
consumers.
Any submissions are due on June 6,
2011.
Issued: May 23, 2011.
By order of the Commission.
James R. Holbein,
Secretary to the Commission.
[FR Doc. 2011–13188 Filed 5–26–11; 8:45 am]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–760]
In the Matter of Certain Liquid Crystal
Display Devices, Products Containing
Same, and Methods for Using the
Same; Notice of Commission Decision
Not To Review an Initial Determination
Terminating the Investigation
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that
the U.S. International Trade
Commission has determined not to
review the presiding administrative law
judge’s initial determination (‘‘ID’’)
(Order No. 9) granting a joint motion to
terminate the investigation.
FOR FURTHER INFORMATION CONTACT:
Sidney A. Rosenzweig, Office of the
General Counsel, U.S. International
Trade Commission, 500 E Street, SW.,
Washington, DC 20436, telephone (202)
708–2532. Copies of non-confidential
documents filed in connection with this
investigation are or will be available for
inspection during official business
hours (8:45 a.m. to 5:15 p.m.) in the
Office of the Secretary, U.S.
International Trade Commission, 500 E
Street, SW., Washington, DC 20436,
telephone (202) 205–2000. General
information concerning the Commission
may also be obtained by accessing its
Internet server at https://www.usitc.gov.
The public record for this investigation
may be viewed on the Commission’s
electronic docket (EDIS) at https://
edis.usitc.gov. Hearing-impaired
persons are advised that information on
this matter can be obtained by
contacting the Commission’s TDD
terminal on (202) 205–1810.
SUPPLEMENTARY INFORMATION: The
Commission instituted this investigation
on March 2, 2011, based on a complaint
filed by Sharp Corporation of Japan
(‘‘Sharp’’) that named as respondents:
AU Optronics Corp. of Taiwan; AU
Optronics Corporation America of
Houston, Texas; BenQ America of
Irvine, California; BenQ Corporation of
jdjones on DSK8KYBLC1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
15:25 May 26, 2011
Jkt 223001
Taiwan; Haier America Trading LLC, of
New York, New York; Haier Group
Company of China; LG Electronics Inc.
of South Korea; LG Electronics U.S.A.,
Inc. of Englewood Cliffs, New Jersey;
SANYO Electric Co. of Japan; SANYO
North America Corporation of San
Diego, California; TCL Corporation of
China; TTE Technology, Inc. d/b/a TCL
America of Indianapolis, Indiana; and
VIZIO, Inc. of Irvine, California. 76 FR
11512 (Mar. 2, 2011). The complaint
alleged a violation of section 337 of the
Tariff Act of 1930, as amended, 19
U.S.C. 1337, in the importation, sale for
importation, and sale within the United
States after importation of certain liquid
crystal display (‘‘LCD’’) devices,
products containing same, and methods
for using same by reason of the
infringement of certain claims of U.S.
Patent Nos. 6,879,364; 7,304,626;
7,532,183; 7,283,192; 6,937,300;
7,057,689; and 7,838,881.
On April 21, 2011, Sharp and the AU
Optronics respondents (‘‘AUO’’) filed a
joint motion for termination of the
investigation on the basis of settlement
and licensing agreements. No other
party opposed the motion. The
agreements call for Sharp and AUO to
terminate the investigation and to
dismiss parallel district court
proceedings. The other respondents
make or sell products that contain
accused AUO LCD components, and the
settlement between Sharp and AUO
thereby resolved all disputes in the
investigation.
On May 3, 2011, the ALJ granted the
motion as an ID (Order No. 9).
No petitions for review of the ID were
filed. The Commission has determined
not to review the ID.
The authority for the Commission’s
determination is contained in section
337 of the Tariff Act of 1930, as
amended (19 U.S.C. 1337), and in Part
210 of the Commission’s Rules of
Practice and Procedure (19 CFR part
210).
By order of the Commission.
Issued: May 23, 2011.
James R. Holbein,
Secretary to the Commission.
[FR Doc. 2011–13189 Filed 5–26–11; 8:45 am]
BILLING CODE 7020–02–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Application
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
PO 00000
Frm 00067
Fmt 4703
Sfmt 4703
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2), authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on March
14, 2011, Almac Clinical Services Inc.
(ACSI), 25 Fretz Road, Souderton,
Pennsylvania 18964, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the following basic
classes of controlled substances:
Drug
Schedule
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Tapentadol (9780) ........................
Fentanyl (9801) ............................
II
II
II
II
The company plans to import small
quantities of the listed controlled
substances in dosage form to conduct
clinical trials.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances may file comments or
objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43, and in such form as
prescribed by 21 CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 27, 2011.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import the basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
E:\FR\FM\27MYN1.SGM
27MYN1
30969
Federal Register / Vol. 76, No. 103 / Friday, May 27, 2011 / Notices
Dated: May 13, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
[FR Doc. 2011–13207 Filed 5–26–11; 8:45 am]
BILLING CODE 4410–09–P
Dated: May 13, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: May 12, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2011–13193 Filed 5–26–11; 8:45 am]
BILLING CODE 4410–09–P
[FR Doc. 2011–13208 Filed 5–26–11; 8:45 am]
jdjones on DSK8KYBLC1PROD with NOTICES
Importer of Controlled Substances;
Notice of Application
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Pursuant to 21 U.S.C. 958(i), the
Attorney General shall, prior to issuing
a registration under this Section to a
bulk manufacturer of a controlled
substance in schedule I or II, and prior
to issuing a regulation under 21 U.S.C.
952(a)(2) authorizing the importation of
such a substance, provide
manufacturers holding registrations for
the bulk manufacture of the substance
an opportunity for a hearing.
Therefore, in accordance with 21 CFR
1301.34(a), this is notice that on March
8, 2010, Akorn, Inc., 1222 W. Grand
Avenue, Decatur, Illinois 62522, made
application to the Drug Enforcement
Administration (DEA) to be registered as
an importer of Remifentanil (9739), a
basic class of controlled substance listed
in schedule II.
The company plans to import
Remifentanil in bulk for use in dosageform manufacturing.
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic class of controlled substance
may file comments or objections to the
issuance of the proposed registration
and may, at the same time, file a written
request for a hearing on such
application pursuant to 21 CFR 1301.43
and in such form as prescribed by 21
CFR 1316.47.
Any such comments or objections
should be addressed, in quintuplicate,
to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than June 27, 2011.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745), all applicants for
registration to import a basic class of
any controlled substance in schedule I
or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
VerDate Mar<15>2010
15:25 May 26, 2011
Jkt 223001
Importer of Controlled Substances;
Notice of Registration
By Notice dated March 8, 2011, and
published in the Federal Register on
March 17, 2011, 76 FR 14688, Aptuit,
10245 Hickman Mills Drive, Kansas
City, Missouri 64137, made application
by renewal to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the following basic
classes of controlled substances:
Drug
I
II
The company plans to import a
finished pharmaceutical product
containing cannabis extracts in dosage
form for packaging for a clinical trial
study. In addition, the company also
plans to import an ointment for the
treatment of wounds which contain
trace amounts of the controlled
substances normally found in poppy
straw concentrate for packaging and
labeling for clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Aptuit to import the basic classes of
controlled substances is consistent with
the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971. DEA has
investigated Aptuit to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
Frm 00068
Fmt 4703
Drug
Schedule
Marihuana (7360) .........................
Poppy Straw Concentrate (9670)
PO 00000
By Notice dated January 18, 2011, and
published in the Federal Register on
February 2, 2011, 76 FR 5827,
Mallinckrodt Inc., 3600 North Second
Street, St. Louis, Missouri 63147, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the
following basic classes of controlled
substances:
Sfmt 4703
Phenylacetone (8501) ..................
Coca Leaves (9040) .....................
Opium, raw (9600) .......................
Poppy Straw Concentrate (9670)
Schedule
II
II
II
II
The company plans to import the
listed controlled substances for the
manufacture of controlled substances in
bulk for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and § 952(a),
and determined that the registration of
Mallinckrodt Inc., to import the basic
classes of controlled substances is
consistent with the public interest, and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. DEA
has investigated Mallinckrodt Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
E:\FR\FM\27MYN1.SGM
27MYN1
]]>Agencies
[Federal Register Volume 76, Number 103 (Friday, May 27, 2011)]
[Notices]
[Pages 30968-30969]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-13207]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Application
Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to
issuing a registration under this Section to a bulk manufacturer of a
controlled substance in schedule I or II, and prior to issuing a
regulation under 21 U.S.C. 952(a)(2), authorizing the importation of
such a substance, provide manufacturers holding registrations for the
bulk manufacture of the substance an opportunity for a hearing.
Therefore, in accordance with 21 CFR 1301.34(a), this is notice
that on March 14, 2011, Almac Clinical Services Inc. (ACSI), 25 Fretz
Road, Souderton, Pennsylvania 18964, made application by renewal to the
Drug Enforcement Administration (DEA) to be registered as an importer
of the following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Oxycodone (9143)............................................ II
Hydromorphone (9150)........................................ II
Tapentadol (9780)........................................... II
Fentanyl (9801)............................................. II
------------------------------------------------------------------------
The company plans to import small quantities of the listed
controlled substances in dosage form to conduct clinical trials.
Any bulk manufacturer who is presently, or is applying to be,
registered with DEA to manufacture such basic classes of controlled
substances may file comments or objections to the issuance of the
proposed registration and may, at the same time, file a written request
for a hearing on such application pursuant to 21 CFR 1301.43, and in
such form as prescribed by 21 CFR 1316.47.
Any such comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than June 27, 2011.
This procedure is to be conducted simultaneously with, and
independent of, the procedures described in 21 CFR 1301.34(b), (c),
(d), (e), and (f). As noted in a previous notice published in the
Federal Register on September 23, 1975, 40 FR 43745-46, all applicants
for registration to import the basic class of any controlled substance
in schedule I or II are, and will continue to be, required to
demonstrate to the Deputy Assistant Administrator, Office of Diversion
Control, Drug Enforcement Administration, that the requirements for
such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and
21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.
[[Page 30969]]
Dated: May 13, 2011.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2011-13207 Filed 5-26-11; 8:45 am]
BILLING CODE 4410-09-P
